糖尿病肾病发病机制及药物研发进展
Progress in pathogenesis and drug development of diabetic kidney disease
糖尿病肾病(diabetic kidney disease,DKD)是糖尿病主要的并发症之一,是一种微血管病变,临床表现为蛋白尿、估算肾小球滤过率(estimated glomerular filtration rate,eGFR)进行性下降,组织形态学改变则表现为系膜增生和基底膜增厚、肾小球硬化和纤维化,是导致终末期肾病(end stage renal disease,ESRD)的主要原因。DKD 的发病机制复杂,遗传因素、能量代谢异常、免疫和炎症、血流动力学异常等因素均参与并影响 DKD 的形成及疾病进展,且复杂分子机制也为 DKD 的模型构建和新药研发带来了极大的挑战,本文综述了近年来 DKD 在发病机制研究、动物疾病模型研究以及新药研发等方面的相关进展,旨在为治疗 DKD 药物开发提供新的思路。
Diabetic kidney disease (DKD), a kind of microvascular lesion, is one of the major complications of diabetes. Clinically, it is characterized by proteinuria, mesangial proliferation and thickening of the basement membrane, glomerular sclerosis and fibrosis, and progressive decline of estimated glomerular filtration rate (eGFR), and is recognized as the main cause of end-stage renal disease (ESRD). The pathogenesis of DKD is complex, with genetic factors, abnormal energy metabolism, immunity and inflammation, and hemodynamic abnormalities all participating in and influencing the formation and progression of DKD. The complex molecular mechanism also brings great challenges to the construction of DKD models and the development of new drugs. This article reviews the recent progress in the research of the pathogenesis of DKD, animal disease models, and new drug development, aiming to provide new ideas for the development of drugs for the treatment of DKD.
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
Wilson PC, Wu H, Kirita Y, |
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
Nicoloff G, Blazhev A, Petrova C, |
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
Wang W, Jiang S, Tang X, |
| [61] |
罗文婷, 唐诗韵, 肖湘, |
| [62] |
钱足平, 陈勇, 冉燕, |
| [63] |
蒋子健, 陈钇地, 龙莉玲, |
| [64] |
|
| [65] |
|
| [66] |
Hu H, Hu J, Chen Z, |
| [67] |
张翠香, 洪晓华, 侯金才, |
| [68] |
|
| [69] |
|
| [70] |
李沛城, 冯波. 《中国糖尿病防治指南 (2024 版)》更新要点解读[J].同济大学学报 (医学版), 2025, 46(2): 151-158. |
| [71] |
中国中西医结合学会内分泌专业委员会. 渴络欣胶囊治疗糖尿病肾脏疾病临床应用专家共识[J].中国中西医结合杂志, 2020, 40(8): 979-984. |
湖南省自然科学基金(2024JJ8140)
湖南省重点研发计划(2023DK2006)
长沙市“小荷”青年人才创新项目(〔2022〕056)
国家自然科学基金(82173809)
国家自然科学基金(82470437)
/
| 〈 |
|
〉 |